# Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis

> **NCT02455167** · PHASE3 · TERMINATED · sponsor: **University of Colorado, Denver** · enrollment: 9 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Simeprivir (SMV)
- **DRUG:** Sofosbuvir (SOF)
- **DRUG:** Ribavirin (RBV)

## Key facts

- **NCT ID:** NCT02455167
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2016-07-18
- **Final completion:** 2016-07-18
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Study stopped due to low accrual and availability of other treatment options
- **Last updated:** 2021-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02455167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02455167, "Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02455167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*